1H NMR investigation on interaction between ibuprofen and lipoproteins

Chemistry and Physics of Lipids

Volumn 148, Issue 2, 2007, Pages 105-111

  Lan, Wenxian ^a,b   Zhu, Hang ^a,b   Zhou, Zhiming ^a,b   Ye, Chaohui ^a   Liu, Maili ^a  

^a Wuhan National Laboratory for Optoelectronics   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Affinity; Antioxidant; Ibuprofen; Interaction; Lipoprotein; NMR

Indexed keywords

HIGH DENSITY LIPOPROTEIN; IBUPROFEN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; SPHINGOMYELIN; ANTIOXIDANT;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; FEMALE; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; MOLECULAR INTERACTION; NUCLEAR OVERHAUSER EFFECT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; BINDING SITE; CHEMISTRY; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION REDUCTION REACTION; SOLUBILITY;

ANTIOXIDANTS; BINDING SITES; HUMANS; HYDROPHOBICITY; IBUPROFEN; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION-REDUCTION; PHOSPHATIDYLCHOLINES; SOLUBILITY; SPHINGOMYELINS;

EID: 34250692631     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chemphyslip.2007.04.012     Document Type: Article

References (39)

1. 1H NMR. Chem. Phys. Lett. 242 (1995) 95-100
2. Bai G.Y., Cui Y.F., Yang Y.H., Ye C.H., and Liu M.L. A competitive low-affinity binding model for determining the mutual and specific sites of two ligands on protein. J. Pharm. Biomed. Anal. 38 (2005) 588-593
3. Barter P., Kastelein J., Nunn A., and Hobbs R. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 168 (2003) 195-211
4. Brown M.S., and Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 232 (1986) 34-47
5. Chen A., and Shapiro M.J. NOE pumping: a novel NMR technique for identification of compounds with binding affinity to macromolecules. J. Am. Chem. Soc. 120 (1998) 10258-10259
6. Chung B.H., Wilkinson T., Geer J.C., and Segrest J.P. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J. Lipid Res. 21 (1980) 284-291
7. Colles S.M., Maxson J.M., Carlson S.G., and Chisolm G.M. Oxidized LDL-induced injury and apoptosis in atherosclerosis-potential roles for oxysterols. Trends Cardiovasc. Med. 11 (2001) 131-138
8. Cui Y.F., Wen J., Sze K.H., Man D., Lin D.H., Liu M.L., and Zhu G. Interaction between calcium-free calmodulin and IQ motif of neurogranin studied by nuclear magnetic resonance spectroscopy. Anal. Biochem. 315 (2003) 175-182
9. Cullen P., and Assmann G. Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering?. Am. J. Cardiol. 80 (1997) 1287-1294
10. Cushley R.J., and Okon M. NMR studies of lipoprotein structure. Annu. Rev. Biophys. Biomol. Struct. 31 (2002) 177-206
11. 1H NMR relaxation investigation of inhibitors interacting with Torpedo californica acetylcholinesterase. J. Magn. Reson. 144 (2000) 129-133
12. Fournier N., Paul J.L., Atger V., Cogny A., Soni T., delaLleraMoya M., Rothblat G., and Moatti N. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 2685-2691
13. Gonen A., Harats D., Rabinkov A., Miron T., Mirelman D., Wilchek M., Weiner L., Ulman E., Levkovitz H., Ben-Shushan D., and Shaish A. The antiatherogenic effect of allicin: possible mode of action. Pathobiology 72 (2005) 325-334
14. Hajduk P.J., Olejniczak E.T., and Fesik S.W. One-dimensional relaxation- and diffusion-edited NMR methods for screening compounds that bind to macromolecules. J. Am. Chem. Soc. 119 (1997) 12257-12261
15. Hevonoja T., Pentikainen M.O., Hyvonen M.T., Kovanen P.T., and Ala-Korpela M. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. BBA Mol. Cell. Biol. Lipids 1488 (2000) 189-210
16. Huang M., Li J.P., Teoh H., and Man R.Y.K. Low concentrations of 17 beta-estradiol reduce oxidative modification of low-density lipoproteins in the presence of vitamin C and vitamin E. Free Radic. Biol. Med. 27 (1999) 438-441
17. Jeener J., Meier B.H., Bachmann P., and Ernst R.R. Investigation of exchange processes by two-dimensional NMR spectroscopy. J. Chem. Phys. 71 (1979) 4546-4553
18. Khrenov A., Sarafanov A., Ananyeva N., Kouiavskaia D., Shima M., Schwinn H., Josic D., and Saenko E. Molecular basis for different ability of low-density and high-density lipoproteins to support activity of the intrinsic Xase complex. Thromb. Res. 105 (2002) 87-93
19. Liu M.L., Nicholson J.K., and Lindon J.C. Analysis of drug-protein binding using nuclear magnetic resonance based molecular diffusion measurements. Anal. Commun. 34 (1997) 225-228
20. 1H diffusion-edited total-correlation NMR spectroscopy. Anal. Chem. 69 (1997) 1504-1509
21. Liu M.L., Mao X.A., Ye C.H., Huang H., Nicholson J.K., and Lindon J.C. Improved WATERGATE pulse sequences for solvent suppression in NMR spectroscopy. J. Magn. Reson. 132 (1998) 125-129
22. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
23. Luo R.S., Liu M.L., and Mao X.A. NMR diffusion and relaxation study of drug-protein interaction. Spectrosc. Acta Pt. A: Mol. Biomol. Spectrosc. 55 (1999) 1897-1901
24. Macura S., and Ernst R.R. Elucidation of cross relaxation in liquids by two-dimensional NMR spectroscopy. Mol. Phys. 41 (1980) 95-117
25. McCoy M.A., and Wyss D.F. Structures of protein-protein complexes are docked using only NMR restraints from residual dipolar coupling and chemical shift perturbations. J. Am. Chem. Soc. 124 (2002) 2104-2105
26. Medek A., Hajduk P.J., Mack J., and Fesik S.W. The use of differential chemical shifts for determining the binding site location and orientation of protein-bound ligands. J. Am. Chem. Soc. 122 (2000) 1241-1242
27. Meyer B., Weimar T., and Peters T. Screening mixtures for biological activity by NMR. Eur. J. Biochem. 246 (1997) 705-709
28. Murphy H.C., AlaKorpela M., White J.J., Raoof A., Bell J.D., Barnard M.L., Burns S.P., and Iles R.A. Evidence for distinct behaviour of phosphatidylcholine and sphingomyelin at the low density lipoprotein surface. Biochem. Biophys. Res. Commun. 234 (1997) 733-737
29. Naderi G.A., Asgary S., Sarraf-Zadegan N., and Shirvany H. Anti-oxidant effect of flavonoids on the susceptibility of LDL oxidation. Mol. Cell. Biochem. 246 (2003) 193-196
30. Tavridou A., Efthimiadis A., Efthimiadis I., and Paschalidou H. Antioxidant effects of simvastatin in primary and secondary prevention of coronary heart disease. Eur. J. Clin. Pharmacol. 62 (2006) 485-489
31. Upston J.M., Kritharides L., and Stocker R. The role of vitamin E in atherosclerosis. Prog. Lipid Res. 42 (2003) 405-422
32. 1H NMR studies on the interaction of beta-carboline derivatives with human serum albumin. J. Magn. Reson. 130 (1998) 281-286
33. Witztum J.L., and Steinberg D. Role of oxidized low-density-lipoprotein in atherogenesis. J. Clin. Invest. 88 (1991) 1785-1792
34. Wu D.H., Chen A.D., and Johnson C.S. An improved diffusion-ordered spectroscopy experiment incorporating bipolar-gradient pulses. J. Magn. Reson. Ser. A 115 (1995) 260-264
35. 1H NMR spectroscopic evidence of interaction between ibuprofen and lipoproteins in human blood plasma. Anal. Biochem. 324 (2004) 292-297
36. 3lP nuclear magnetic resonance. Biochemistry 16 (1977) 3487-3491
37. 31P nuclear magnetic resonance. Biochemistry 17 (1978) 2707-2710
38. Zapolska-Downar D., Zapolski-Downar A., Bukowska H., Galka H., and Naruszewicz M. Ibuprofen protects low density lipoproteins against oxidative modification. Life Sci. 65 (1999) 2289-2303
39. Zapolska-Downar D., Naruszewicz M., Zapolski-Downar A., Markiewski M., Bukowska H., and Millo B. Ibuprofen inhibits adhesiveness of monocytes to endothelium and reduces cellular oxidative stress in smokers and non-smokers. Eur. J. Clin. Invest. 30 (2000) 1002-1010